Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.
Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.
复制标题
DOI:
10.4049/jimmunol.181.10.7186
复制
发表时间:
2008-11-15
期刊:
影响因子:
--
通讯作者:
Arditi M
中科院分区:
文献类型:
--
作者:
Chen S;Sorrentino R;Shimada K;Bulut Y;Doherty TM;Crother TR;Arditi M
Chlamydia pneumoniae is detected by macrophages and other antigen presenting cells via Toll-like receptors (TLRs), and can exacerbate developing atherosclerotic lesions, but how that occurs is not known. Liver X receptors (LXRs) centrally control reverse cholesterol transport, but also negatively modulate TLR-mediated inflammatory pathways. We isolated peritoneal macrophages from wild type, TLR2, TLR3, TLR4, TLR2/4, MyD88, TRIF, MyD88/TRIF and IRF3 knockout mice and treated them with live or UV-killed C. pneumoniae in the presence or absence of oxidized LDL (ox-LDL), then measured foam cell formation. In some experiments, the synthetic LXR agonist GW3965 was added to macrophages infected with C. pneumoniae in the presence of ox-LDL. Both live and UV-killed C. pneumoniae induced IRF3 activation and promoted foam cell formation in wild type macrophages, while the genetic absence of TLR2, TLR4, MyD88, TRIF, or IRF3 but not TLR3 significantly reduced foam cell formation. C. pneumoniae-induced foam cell formation was significantly reduced by the LXR agonist GW3965, which in turn inhibited C. pneumoniae-induced IRF3 activation, suggesting a bidirectional cross talk. We conclude that C. pneumoniae facilitates foam cell formation via activation of both MyD88-dependent and MyD88-independent (i.e. TRIF- dependent and IRF3-dependent) pathways downstream of TLR2 and TLR4 signaling, and that TLR3 is not involved in this process. This mechanism could at least partly explain why infection with C. pneumoniae accelerates development of atherosclerotic plaque, and lends support to the proposal that LXR agonists might prove clinically useful in suppressing atherogenesis.